We have demonstrated that both purified CST6 and BM serum from patients with high CST6 expression suppress osteoclast function and differentiation in a CST6-dependent fashion and that recombinant CST6 inhibits bone disease in an in vivo myeloma mouse model. The gene discussed is CST6; the disease is plasma cell myeloma.